Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
waited about eight months to get my second vaccine/date of her first shot was in May 2025, the date of her second shot was 24JAN2026; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 57-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (Received 1st dose of Shingrix vaccine in MAY-2025). On 24-JAN-2026, the patient received the 2nd dose of Shingrix. On 24-JAN-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: waited about eight months to get my second vaccine/date of her first shot was in May 2025, the date of her second shot was 24JAN2026). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 26-JAN-2026 The patient waited about eight months to get the second vaccine. The patient wanted to know if she was still protected since she waited so long. The batch number was not provided and a request for this information has been made.